- Home
- JBLU vs AKRO Comparison
JBLU vs AKRO Comparison
Compare JBLU & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBLU | AKRO |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | JBLU | AKRO |
|---|---|---|
| Price | $4.79 | $54.65 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $4.76 | ★ $73.56 |
| AVG Volume (30 Days) | ★ 17.2M | 2.4M |
| Earning Date | 01-27-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,095,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $21.34 |
| 52 Week High | $8.31 | $58.40 |
Technical Indicators
Market Signals| Indicator | JBLU | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 68.63 |
| Support Level | $4.76 | $54.30 |
| Resistance Level | $5.15 | $54.70 |
| Average True Range (ATR) | 0.22 | 0.17 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 50.04 | 71.07 |
Price Performance
Historical ComparisonAbout JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.